| Co-Investigator(Kenkyū-buntansha) |
TAKEYAMA Hiromitsu 名古屋市立大学, 大学院医学研究科, 教授 (00216946)
TAKAHASHI Hiroki 名古屋市立大学, 大学院医学研究科, 講師 (30381792)
MORIMOTO Mamoru 名古屋市立大学, 大学院医学研究科, 臨床研究医 (60722569)
OKADA Yuji 名古屋市立大学, 大学院医学研究科, 講師 (10305550)
SHIBATA Takahiro 名古屋市立大学, 大学院医学研究科, 助教 (90592501)
|
|---|
| Budget Amount *help |
¥13,780,000 (Direct Cost: ¥10,600,000、Indirect Cost: ¥3,180,000)
Fiscal Year 2015: ¥4,420,000 (Direct Cost: ¥3,400,000、Indirect Cost: ¥1,020,000)
Fiscal Year 2014: ¥4,420,000 (Direct Cost: ¥3,400,000、Indirect Cost: ¥1,020,000)
Fiscal Year 2013: ¥4,940,000 (Direct Cost: ¥3,800,000、Indirect Cost: ¥1,140,000)
|
|---|
| Outline of Final Research Achievements |
We previously reported that tumor derived angiogenic factors such as VEGF and IL-8 play important role in progression of gastrointestinal cancer via cancer stromal interaction. Protein kinase D (PKD) is a family of serine/threonine kinases and diacylglycerol receptors that signal downstream of G protein-coupled receptors. The purpose of this study was to elucidate the role of PKD signaling in gastrointestinal cancer angiogenesis. Initially we confirmed that the regulation of PKD signaling inhibited the proliferation, invasion, and angiogenesis in pancreatic cancer. Next we confirmed that both mRNA and protein expression of these angiogenic factors were enhanced by PMA and that the enhancement was inhibited by PKD inhibitor. Our results indicate that PKD play an important role in angiogenesis of gastrointestinal cancer and PKD inhibitor has a potential to become a new anti-angiogenic drug.
|
